The Disease Isn't the Person
Here's something most people don't want to hear: Alzheimer's doesn't erase who someone is. It takes away their memory of what they did, sure. But the person underneath? The one who still flinches at a raised voice or lights up when they hear a favorite song? That one stays. I've seen it in the literature, and more importantly, I've read the accounts from families who live this daily. The care models that work — really work — are built on that stubborn truth.
We're living through a strange moment in dementia care. On one hand, we've got the most aggressive drug development push in neurology history. On the other, we're finally — painfully slowly — catching on to what caregivers have known for decades: that dignity isn't a luxury, it's a clinical necessity. This shift is crucial, especially when we consider the widespread brain health knowledge gap among older adults who often overlook the daily habits that can reduce dementia risk. Both clinical and social movements matter, and neither alone is enough.
The New Drugs: Promises and Realities
Two drugs have earned FDA approval for early Alzheimer's disease: donanemab (Kisunla®) and lecanemab (Leqembi®). They work differently from anything we had before. Older medications — the cholinesterase inhibitors, the memantine — they patched symptoms. They made someone a bit more alert for a few months, maybe. These new ones actually target beta-amyloid plaques, the protein clumps thought to drive cognitive decline. They remove the plaques. That's a fundamentally different approach.
Do they cure Alzheimer's? No. Nobody's curing anything yet. But they slow cognitive decline, and for people in the early stages, that slowdown can mean months or even a year or two of additional clarity. That's not nothing.
Here's where it gets complicated, and I think we owe families an honest conversation about it. These drugs demand intensive monitoring. Monthly MRIs. Not because the treatment is mildly inconvenient, but because there are real — and rare — side effects: brain swelling, microbleeds. You're asking someone to sit through a lot of scanning to buy themselves some time.
And then there's the cost question. Insurance coverage varies wildly between Medicare, private plans, and individual health policies. Some families get it covered. Others get a bill they can't parse. Access to these treatments remains uneven, and that's a policy failure we haven't adequately addressed.
Aducanumab: The Cautionary Chapter
We should mention aducanumab (Aduhelm®), the drug that came before both donanemab and lecanemab. It was approved under controversial circumstances — the clinical data showing insufficient benefit, combined with safety concerns that made many neurologists uncomfortable. It's been discontinued now. The lesson isn't just "bad drug goes away." The lesson is that the field learned from it. Both Kisunla and Leqembi entered trials with more rigorous endpoints, more transparent data sharing, and a clearer understanding that approval without convincing evidence erodes public trust.
That's progress. Ugly, slow progress, but real.
Designing for Dignity
Walk into a modern Alzheimer's special care unit and you'll notice something immediately: it doesn't feel like a hospital. The dining room has height-adjustable tables so residents can eat comfortably regardless of mobility. Photographs hang beside each person's door — usually two: one from their youth or prime, another recent. It sounds small. It isn't.
Julie Bree, associate director of Allied Services, told me (through the Psychology Today reporting by Dr. Thomas Verny) that her job is fundamentally about enhancing residents' quality of life. She's been at this facility for twenty years. Twenty. And when I asked her how she sustains that commitment in an environment most people find emotionally draining, she said simply: she loves her work. The best moments, she told him, are watching someone anxious or withdrawn begin to relax and reconnect.
That's not a policy document. That's a human being doing hard work with intention.
The Person Behind the Diagnosis
Audra Young, a DementiAbility educator who consults with memory care units across North America, puts it plainly: dementia care rests on the premise that memory loss does not eliminate the need for emotional connection. That single sentence should be posted in every staff break room.
Her work focuses on training caregivers to see the person, not the pathology. Using residents' names. Encouraging participation in activities even when engagement looks different than it used to. Validating emotional needs — fear, frustration, love — even when the person can't articulate why they feel that way. Programs like DementiAbility have shown that behavioral symptoms often decrease when staff shift from control-based approaches to connection-based ones.
The activities in these units aren't filler. They're therapeutic by design: stimulating cognition, maintaining abilities for as long as possible, reducing the anxiety and agitation that so often accompany dementia. Every puzzle, music session, or shared meal is an intervention.
The Caregiver Reality
Let's talk about the people holding this all together at home. Over 7 million Americans live with Alzheimer's. Thirteen million caregivers support them. The Alzheimer's Association runs a free 24/7 helpline, local chapter resources, support groups, and educational workshops — all of it accessible through alz.org.
Caregiving is exhausting. Emotionally, physically, financially—especially when these duties overlap with other major life phases, as explored in our guide on managing the physical and financial costs of family caregiving. But here's what the research and the lived accounts both reveal: many caregivers discover unexpected strengths. Patience they didn't know they had. Advocacy skills forged in hospital corridors and insurance calls. A recalibrated sense of what actually matters.
This isn't romanticization. Hardship is hardship. But difficulty, when met and moved through, can become a source of growth. Tending another life enriches your own, even when it breaks you open first.
What This All Means
The cultural shift happening in dementia care right now is bigger than any single drug or policy. We're moving from a model that manages disease to one that honors personhood. The new medications are tools — powerful, imperfect, expensive tools. But the real transformation is in how society sees and treats people living with dementia.
They deserve to be seen. Known. Valued. Regardless of age. Regardless of cognitive ability.
The professionals I've read about — Dr. Verny's interviews with Julie Bree, Audra Young's consultations across facilities — they share a grounding belief: every person deserves dignity until the very end. In an era defined by division and self-interest, that belief is radical. And it's worth fighting for.